Navigation Links
Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
Date:6/3/2009

JERUSALEM, June 3 /PRNewswire/ -- The Gamida Cell-Teva Joint Venture announced today that five prestigious cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the Excel study.

    Participating clinical sites include, in alphabetical order:

    - Hospital Clinic of Barcelona, Barcelona

    Principal Investigator, Dr. Enric Carreras, MD

    - Hospital Clinico Universitario de Valencia, Valencia

    Principal Investigator, Dr. Cristina Arbona, MD

    - Hospital de la Santa Creu i Sant Pau, Barcelona

    Principal Investigator, Dr. Jorge Sierra, MD

    - Hospital Germans Trias i Pujol, Barcelona

    Principal Investigator, Dr. Christelle Ferra, MD

    - Hospital Universitario La Fe, Valencia

    Principal Investigator, Dr. Guillermo Sanz, MD

The trial is assessing the safety and efficacy of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal marketing authorization trial. StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells from the same unit. StemEx(R) is being developed by a Joint Venture of Gamida Cell and Teva Pharmaceutical Industries (NASDAQ: TEVA).

Excel is a study that gives clinicians the opportunity to explore a new path in the pursuit of a therapeutic treatment for patients with blood cancers. Cord blood can successfully be used to treat leukemia and lymphoma in young children. It stands to reason therefore that the same basic source could also be used to effectively treat adolescents and adults. The Excel trial provides an opportunity to determine if StemEx can indeed make this a possibility.

Cord blood has less matching requirements than bone marrow or peripheral blood transplants, providing the potential to increase the number of suitable transplant matches and to shorten the time it can take to find a match. However, there are a limited number of stem/progenitor cells in cord blood, enabling a quantity sufficient generally only for pediatric treatment. StemEx(R) employs a technology that expands this small number of cord blood stem/progenitor cells, increasing their therapeutic capacity for transplantation in adolescents and adults.

It is estimated that more than 11,000 patients in the European Union are in need of an allogeneic (from a source outside of the patient's body) hematopoietic (blood) stem cell transplantation. This is an unofficial figure calculated based on the method proposed by the US government's General Accounting Office (GAO) report and The EBMT Activity Survey 2006 on Hematopoietic Stem Cell Transplantation: Focus on the Use of Cord Blood Products.

"We are enthusiastic about working with these five outstanding hospitals in Spain, the esteemed principal investigators and their experienced staves. Together, we hope to demonstrate the advantage of the StemEx transplant for patients," said Dr. David Snyder, vice president of clinical development at Gamida Cell.

About Gamida Cell

Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. The company is developing a pipeline of products in stem cell transplantation and in tissue regeneration to effectively treat debilitating and often fatal illnesses such as cancer, hematological, autoimmune and ischemic diseases. Gamida Cell's therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood and bone marrow, which are expanded in culture. Gamida Cell was successful in translating these proprietary expansion technologies into robust and validated manufacturing processes under GMP. Gamida Cell's flagship product, StemEx, is now being studied as a therapy for patients with blood cancers in an international pivotal trial at leading transplant centers in the U.S., Europe and Israel. StemEx has orphan drug designation in the U.S. and in Europe. Gamida Cell's current shareholders include: Elbit Imaging, Biomedical Investment, Israel Healthcare Venture, Teva Pharmaceutical Industries, Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com. For information regarding the Excel study: http://www.stemexstudy.com.

Press contacts: Marjie Hadad, Gamida Cell, +972-54-536-5220 or marjie@gamida-cell.com; Marc de Semir, H. Clinic i Provincial de Barcelona at mdesemir@clinic.ub.es or +34-93-227-57-00


'/>"/>
SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
2. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
3. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
4. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
5. CDC Awards NATT Funding to Improve Blood Clot Awareness
6. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
7. Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis
8. Blood Donations in U.S. Testing Positive for Chagas Disease
9. One of Nations Oldest Blood Services Providers Turns to Sysmex America
10. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
11. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... ... of biologics. To acquire information on the desired increase and/or decrease in antibody-dependent ... industry for rapid N-glycosylation profiling of therapeutic antibodies. , To meet this ...
(Date:3/22/2017)... (PRWEB) , ... March 21, ... ... ( WMFTG ) has unveiled its innovative Quantum peristaltic pump with patented ... innovation, Quantum sets the new standard for high-pressure feed pumps in SU ...
(Date:3/22/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... Lebovits , Chief Executive Officer, will provide an update ... Associates 2 nd Annual Neuroscience Biopartnering and Investment ... the New York Academy of Sciences. ...
Breaking Biology Technology:
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):